Generics BulletinMarking its first year of being a fully integrated biosimilars company , Biocon Biologics has a packed calendar with five launches expected over the next 12 to 18 months. These products include off-p
Generics BulletinBiocon Limited is looking to raise INR45bn ($526.95m), largely to meet debt obligations from the investment in its subsidiary Biocon Biologics. During the earnings call for the fiscal fourth quarter a
Generics BulletinTeva and Alvotech have celebrated receiving an interchangeability designation for their partnered Selarsdi (ustekinumab-aekn) biosimilar to Stelara in the US, allowing the product to be substituted at
Generics BulletinFour biosimilars sponsors – Biocon Biologics, Gedeon Richter, Mabxience and Zentiva – have each received dual positive opinions from the European Medicines Agency’s Committee for Medicinal Products fo